BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38635786)

  • 1. Primary Large B-cell Lymphomas of Immune-Privileged Sites.
    Roschewski M; Phelan JD; Jaffe ES
    Blood; 2024 Apr; ():. PubMed ID: 38635786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYD88
    Chen R; Zhou D; Wang L; Zhu L; Ye X
    Ther Adv Hematol; 2022; 13():20406207211072839. PubMed ID: 35126963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell.
    Los-de Vries GT; Stathi P; Rutkens R; Hijmering NJ; Luijks JACW; Groenen PJTA; de Jong D; Ylstra B; Roemer MGM
    Cancer Res; 2023 Jun; 83(11):1917-1927. PubMed ID: 36971477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.
    King RL; Goodlad JR; Calaminici M; Dotlic S; Montes-Moreno S; Oschlies I; Ponzoni M; Traverse-Glehen A; Ott G; Ferry JA
    Virchows Arch; 2020 May; 476(5):647-665. PubMed ID: 31863183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy.
    Phelan JD; Scheich S; Choi J; Wright GW; Häupl B; Young RM; Rieke SA; Pape M; Ji Y; Urlaub H; Bolomsky A; Doebele C; Zindel A; Wotapek T; Kasbekar M; Collinge B; Huang DW; Coulibaly ZA; Morris VM; Zhuang X; Enssle JC; Yu X; Xu W; Yang Y; Zhao H; Wang Z; Tran AD; Shoemaker CJ; Shevchenko G; Hodson DJ; Shaffer AL; Staudt LM; Oellerich T
    Cancer Cell; 2024 Feb; 42(2):238-252.e9. PubMed ID: 38215749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
    Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
    Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
    Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.
    Kraan W; Horlings HM; van Keimpema M; Schilder-Tol EJ; Oud ME; Scheepstra C; Kluin PM; Kersten MJ; Spaargaren M; Pals ST
    Blood Cancer J; 2013 Sep; 3(9):e139. PubMed ID: 24013661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
    Ollila TA; Olszewski AJ
    Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
    Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
    Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
    Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular diagnostics for vitreoretinal lymphoma].
    Bonzheim I; Salmerón-Villalobos J; Süsskind D; Szurman P; Gekeler F; Spitzer MS; Salaverria I; Campo E; Coupland SE; Quintanilla-Martinez L; Fend F
    Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):150-154. PubMed ID: 37947807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
    Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
    Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
    Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM
    N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
    Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
    J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez Pereña A; Marcos Gonzalez S; Teran-Villagra N; Azueta A; Batlle A; Gonzalez de Villambrosia S; Revert Arce J; Montes-Moreno S
    Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):e68-e71. PubMed ID: 29629945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
    Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
    J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.
    Frauenfeld L; Castrejon-de-Anta N; Ramis-Zaldivar JE; Streich S; Salmerón-Villalobos J; Otto F; Mayer AK; Steinhilber J; Pinyol M; Mankel B; Ramsower C; Bonzheim I; Fend F; Rimsza LM; Salaverria I; Campo E; Balagué O; Quintanilla-Martinez L
    Blood Adv; 2022 Apr; 6(7):2361-2372. PubMed ID: 34654055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genomic and transcriptional landscape of primary central nervous system lymphoma.
    Radke J; Ishaque N; Koll R; Gu Z; Schumann E; Sieverling L; Uhrig S; Hübschmann D; Toprak UH; López C; Hostench XP; Borgoni S; Juraeva D; Pritsch F; Paramasivam N; Balasubramanian GP; Schlesner M; Sahay S; Weniger M; Pehl D; Radbruch H; Osterloh A; Korfel A; Misch M; Onken J; Faust K; Vajkoczy P; Moskopp D; Wang Y; Jödicke A; Trümper L; Anagnostopoulos I; Lenze D; Küppers R; Hummel M; Schmitt CA; Wiestler OD; Wolf S; Unterberg A; Eils R; Herold-Mende C; Brors B; ; Siebert R; Wiemann S; Heppner FL
    Nat Commun; 2022 May; 13(1):2558. PubMed ID: 35538064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.